Frequently Asked Questions

BEACON NSCLC-04 is a clinical trial evaluating a new investigational combination therapy for adults with non-small cell lung cancer. The study aims to determine whether this treatment can improve outcomes compared to currently available options.

Adults aged 18 and older with a confirmed diagnosis of non-small cell lung cancer (NSCLC) may be eligible. Specific eligibility criteria include prior treatment history, overall health status, and other factors that your study team will review with you.

The study is designed to evaluate the safety and effectiveness of the investigational combination therapy. Researchers will assess how well the treatment works, how participants tolerate it, and whether it offers benefits over existing standard-of-care treatments.

Contact your nearest study site to schedule a screening visit. During screening, the study team will review your medical history, perform assessments, and determine whether you meet the eligibility criteria.

Participants will receive the investigational combination therapy over a series of treatment cycles. Each cycle includes study visits for treatment administration, health assessments, and lab work. The study team will monitor your progress throughout.

The active treatment period varies by participant but typically lasts several months. Follow-up visits continue after treatment ends to monitor long-term health outcomes.

Yes. Participation is completely voluntary and you may withdraw at any time, for any reason, without it affecting your standard medical care or relationship with your healthcare providers.

All study-related care, medication, and procedures are provided at no cost to you. Depending on your study site, travel reimbursement and additional support may also be available.

During active treatment, visits typically occur every two to three weeks. Each visit usually takes two to four hours, depending on the assessments scheduled that day.

No. Study participation is coordinated with your existing care team. The research site communicates with your oncologist to ensure continuity of care throughout the study.

The study team monitors your health closely throughout the trial. If you experience side effects, the team will manage them and adjust your treatment if needed. You should report any new symptoms to your study team promptly.

Your privacy is protected by federal regulations and the study protocol. Personal information is coded and kept confidential. Only authorized study personnel have access to your identifiable data.

The study team monitors your response throughout treatment. If the therapy is not providing benefit or if side effects become a concern, the team will discuss next steps and alternative options with you.